Lakewood-Amedex Biotherapeutics, Bisphosphocin, Nu-8, Nu-3, Antimicrobial Resistance, AMR, Urinary Tract Infection, UTI, Pulmonary Infection, E. coli, Pseudomonas aeruginosa, Klebsiella pneumoniae

Sarasota, Florida, U.S., October 7, 2026 Lakewood-Amedex Biotherapeutics has announced positive preclinical data supporting the potential of its Bisphosphocin®...